OBJECTIVE
To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life.
DESIGN
Multisite, randomized, double-blind, placebo-controlled clinical trial.
SETTING
MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Ph...